Kataoka Kosuke, Fujihashi Kohtaro
Department of Preventive Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
Expert Rev Vaccines. 2009 Sep;8(9):1183-93. doi: 10.1586/erv.09.80.
In order to establish effective mucosal immunity against various mucosal pathogens, vaccines must be delivered via the mucosal route and contain effective adjuvant(s). Since mucosal adjuvants can simply mix with the antigen, it is relatively easy to adapt them for different types of vaccine development. Even in simple admixture vaccines, the adjuvant itself must be prepared without any complications. Thus, CpG oligodeoxynucleotides or plasmids encoding certain cDNA(s) would be potent mucosal adjuvant candidates when compared with other substances that can be used as mucosal adjuvants. The strategy of a DNA-based mucosal adjuvant facilitates the targeting of mucosal dendritic cells, and thus is an effective and safe approach. It would also provide great flexibility for the development of effective vaccines for various mucosal pathogens.
为了建立针对各种黏膜病原体的有效黏膜免疫，疫苗必须通过黏膜途径递送并包含有效的佐剂。由于黏膜佐剂可以简单地与抗原混合，因此将它们应用于不同类型的疫苗开发相对容易。即使在简单的混合疫苗中，佐剂本身的制备也必须没有任何并发症。因此，与其他可用作黏膜佐剂的物质相比，CpG寡脱氧核苷酸或编码某些cDNA的质粒将是有效的黏膜佐剂候选物。基于DNA的黏膜佐剂策略有助于靶向黏膜树突状细胞，因此是一种有效且安全的方法。它还将为开发针对各种黏膜病原体的有效疫苗提供极大的灵活性。
